What is the appropriate management of aortic regurgitation?

Management of Aortic Regurgitation

Aortic valve replacement (AVR) is indicated for symptomatic patients with severe AR, asymptomatic patients with LVEF <55%, and asymptomatic patients with severe LV dilation (LVESD >50 mm or indexed LVESD >25 mm/m²), with surgery remaining the gold standard and transcatheter approaches reserved for high/prohibitive surgical risk patients. 1

Algorithmic Approach to Management

Stage D: Symptomatic Severe AR

• Class I indication for AVR regardless of LV function 1
• Symptoms include dyspnea, heart failure, angina, or reduced exercise capacity
• These patients have high mortality risk without intervention and require urgent evaluation by a multidisciplinary valve team 1

Stage C2: Asymptomatic Severe AR with LV Dysfunction

• Class I indication for AVR when LVEF <55% 1
• This threshold is critical because outcomes deteriorate significantly once ejection fraction drops below this level
• Recent evidence suggests mortality increases when LVEF falls below 55%, supporting earlier intervention 2

Stage C2: Asymptomatic Severe AR with Severe LV Dilation

• Class IIa indication for AVR when:
  • LVESD >50 mm OR
  • Indexed LVESD >25 mm/m² 1
• Normal LV systolic function (LVEF >55%) must be present
• These dimensional criteria identify patients at risk for irreversible LV remodeling before systolic dysfunction develops

Stage C1: Asymptomatic Severe AR with Progressive Changes

• Class IIb indication for AVR when low surgical risk AND at least 3 serial studies show:
  • Progressive LVEF decline to 55-60% (low-normal range) OR
  • Progressive LV dilation with LVEDD >65 mm 1
• This represents earlier intervention to prevent irreversible consequences of volume overload
• Emerging data suggest intervention before traditional triggers may improve long-term outcomes, with mortality increasing when LVESD exceeds 20-22 mm/m² 2

Concurrent Cardiac Surgery

• Class I indication: Add AVR when performing cardiac surgery for other indications in patients with severe AR 1
• Class IIa indication: Consider AVR for moderate AR during other cardiac/aortic surgery 1

Surgical vs. Transcatheter Approach

Surgical AVR (SAVR)

• Remains the gold standard for native AR 1, 3
• Preferred for most surgical candidates
• Valve-sparing procedures may be considered in selected patients with favorable anatomy undergoing aortic root surgery 1
• Choice between mechanical and bioprosthetic valves should involve shared decision-making considering age, anticoagulation tolerance, and patient preference

Transcatheter AVR (TAVR)

• Class III (Harm) recommendation: TAVR should NOT be performed in isolated severe AR when patient is a surgical candidate 1
• May be considered for high or prohibitive surgical risk patients, though devices designed for calcific stenosis face technical challenges in AR (large non-calcified annuli, risk of embolization, paravalvular leak) 3
• Purpose-built AR devices show promise but remain investigational in the U.S. 3

Medical Management

Vasodilator Therapy

• ACE inhibitors or ARBs may reduce systolic blood pressure in chronic AR without substantially reducing diastolic pressure 1
• These agents do not affect heart rate, unlike beta blockers which may paradoxically increase blood pressure by reducing heart rate and increasing stroke volume 1
• Important caveat: Medical therapy does not replace timely surgical intervention and should not delay surgery in patients meeting operative criteria

Surveillance Strategy

Imaging Modalities

• Transthoracic echocardiography is primary modality for diagnosis and serial monitoring 1, 4
• Cardiac MRI provides superior quantification of regurgitant volume, LV volumes, and may detect earlier remodeling 3, 5
• Consider advanced imaging (CMR, 4D flow, speckle-tracking echo) when echocardiography is discordant with clinical findings 1, 3

Monitoring Frequency

• Serial studies (at least 3) are essential to document progression and guide timing of intervention 1
• Biomarkers and global longitudinal strain are emerging tools but require additional validation 1

Critical Pitfalls to Avoid

1. Waiting too long: Class I triggers (symptoms, LVEF <55%, severe dilation) are associated with worse postoperative outcomes 2. Consider intervention before these thresholds in low-risk patients with progressive changes.

2. Relying solely on LVEDD: LV end-diastolic dimension does not influence outcomes as strongly as LVESD 6, 2. Focus on end-systolic dimensions and ejection fraction.

3. Body size adjustment in smaller patients: Indexed LVESD of 25 mm/m² may overcorrect in patients with small body habitus 6. Use absolute LVESD >50 mm as primary criterion.

4. Attempting TAVR in surgical candidates: Current TAVR devices are suboptimal for native AR and carry Class III (Harm) recommendation 1.

5. Underestimating symptom progression: Patients may gradually reduce activity and not recognize symptoms. Detailed history and exercise testing are essential 1.

Multidisciplinary Evaluation

All patients with severe AR being considered for intervention should be evaluated by a multidisciplinary valve team, with referral to or consultation with a Primary or Comprehensive Valve Center 1. This ensures optimal risk stratification, procedural planning, and shared decision-making regarding mechanical vs. bioprosthetic valves and surgical approach.